Y Intercept Hong Kong Ltd Buys Shares of 8,983 Prestige Consumer Healthcare Inc. (NYSE:PBH)

Y Intercept Hong Kong Ltd bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 8,983 shares of the company's stock, valued at approximately $648,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. MML Investors Services LLC lifted its holdings in Prestige Consumer Healthcare by 16.5% in the third quarter. MML Investors Services LLC now owns 4,328 shares of the company's stock worth $312,000 after acquiring an additional 612 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter worth about $264,000. Jane Street Group LLC lifted its position in Prestige Consumer Healthcare by 28.3% in the 3rd quarter. Jane Street Group LLC now owns 65,373 shares of the company's stock valued at $4,713,000 after purchasing an additional 14,434 shares during the last quarter. Wellington Management Group LLP bought a new position in Prestige Consumer Healthcare in the 3rd quarter worth about $6,342,000. Finally, WESCAP Management Group Inc. grew its holdings in Prestige Consumer Healthcare by 5.3% in the 3rd quarter. WESCAP Management Group Inc. now owns 18,892 shares of the company's stock worth $1,362,000 after buying an additional 945 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock traded down $1.28 during midday trading on Friday, hitting $82.30. The company had a trading volume of 241,429 shares, compared to its average volume of 251,842. The stock has a market cap of $4.07 billion, a PE ratio of 20.02, a P/E/G ratio of 2.35 and a beta of 0.49. Prestige Consumer Healthcare Inc. has a 1-year low of $57.95 and a 1-year high of $86.36. The business's 50 day simple moving average is $78.12 and its two-hundred day simple moving average is $72.54. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same quarter last year, the company earned $1.07 EPS. The company's quarterly revenue was down .9% on a year-over-year basis. As a group, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Adel Mekhail sold 9,063 shares of the firm's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares of the company's stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 over the last quarter. Company insiders own 1.60% of the company's stock.

Wall Street Analysts Forecast Growth

PBH has been the topic of a number of research analyst reports. StockNews.com lowered Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. DA Davidson reaffirmed a "buy" rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group reiterated a "hold" rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Finally, Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $85.25.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.